The incidence of DNMT3A- and TET2-CHIP-driver mutations in a cohort of 279 total patients undergoing TAVI for severe calcified AS was assessed to determine whether there was any association between CHIP’s inflammatory blood cell phenotype and clinical outcomes. This evidence concerns the gene TET2 and aortic stenosis.